Picture of CVS Health logo

CVS — CVS Health News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapSuper Stock

CVS’s problem: investors trust the warning label

RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

By Robert Cyran

- CVS Health CVS.N has spent the last 20 years expanding its business from drug stores into pharmacy benefit management, insurance, home health care and beyond. On Tuesday, the sprawling conglomerate kicked things into reverse, announcing a plan to spin off its pharmacy business in 2028. Investors responded by knocking $14 billion off the company’s value. Perhaps it’s simply a case of shareholders taking management’s original prescription seriously.

When once-sleepy pharmacy chain CVS agreed to buy drug benefit manager Caremark in 2007, it projected cost savings exceeding $500 million. A decade later, it struck a $70 billion deal to buy insurer Aetna, promising $750 million of near-term synergies. And just three years ago, then boss Karen Lynch touted a $500 million benefit from melding with primary care provider Oak Street Health.

Combined, that’s just under $1.8 billion of promised profit boosts. Tax this figure at the statutory corporate rate and capitalize it on a value of 10, and they might be worth just under $14 billion. That matches neatly with the share-price reaction on Tuesday.

Reality is probably a bit more complicated. The math ignores other promised benefits, like the over-$1 billion of additional revenue foreseen in 2008 from combining with Caremark, and more in additional years. There were inevitable disruptions and legal issues that resulted from the combinations, including lengthy court delays, that might strike again in any unwinding. Worse, it’s simply retreading past decisions after a decade in which CVS’s shares badly underperformed the broader market.

There still might be benefits to a break-up. The two operations will have differing needs for capital. The retail stores might be run as a cash cow, returning excess money to shareholders or paying down some of a company-wide $57 billion debt burden. Other CVS units, meanwhile, might need to invest for growth.

Yet the pharmacy business remains a difficult one, and an independent spin-off faces imposing rivals like Walmart WMT.O that use medications as a way to get customers through the doors. Insurers and drug benefit managers, meanwhile, are frantically trying to cut the amount they pay per filled prescription.

Splitting up solves nothing about this dilemma and adds a distraction for management for over a year. Savings or strategic benefits that did actually result from pushing these operations together might evaporate. Earnings released alongside the reshuffle plan showed revenue growing and earnings recovering. Perhaps sticking to the instructions on the original label is the best plan.

Follow Pranav Kiran on Bluesky and X.

CONTEXT NEWS

CVS Health said on November 4 it would split into two companies in a tax-free transaction.

A new company, called CVS Pharmacy, will contain approximately 9,000 pharmacies, mail prescriptions and in-store clinics. The company estimates this business will have $145 billion of revenue this year.

The other business, which will carry the CVS Health name for now, will comprise the Aetna insurance unit, a pharmacy benefit manager, Oak Street Health clinics for seniors, home healthcare provider Signify Health, and specialty drugs.

The company expects to complete the breakup in the first half of 2028.


(Editing by Jonathan Guilford; Production by Pranav Kiran)

((((For previous columns by the author, Reuters customers can click on CYRAN/ robert.cyran@thomsonreuters.com ; Reuters Messaging: robert.cyran.thomsonreuters.com@reuters.net ))))

Recent news on CVS Health

See all news